Skip to content
Winnowleaf home

Supplements and Kidney Health in Diabetes: What's Studied, What to Avoid

Supplements have not matched prescribed medicines at protecting kidneys in diabetes, and the 2022 KDIGO guideline relies on medicines. In a 5-year trial of 1,312 adults with type 2 diabetes, vitamin D3 and omega-3 made no clear difference to kidney function (grade B). Ginkgo and alpha-lipoic acid, added to blood-pressure medicines, lowered urine albumin, a lab marker (grade C). Talk to your nephrologist (kidney doctor) first: potassium salt substitutes, some herbs and high-dose vitamin C can harm damaged kidneys.

Published How we grade evidenceEditorial policy

The short version

  • Vitamin D3 and omega-3: no clear difference in kidney function after 5 years in 1,312 adults with type 2 diabetes. Grade B (de Boer 2019).
  • Ginkgo or alpha-lipoic acid added to a blood-pressure drug: lower urine albumin, a lab marker. Grade C (Zhang 2024; Sun 2021).
  • Turmeric, curcumin and probiotics: mixed results on kidney lab tests. Grade C (Bahari 2026; Huang 2026).
  • Benfotiamine: urine albumin did not fall. Grade D (Alkhalaf 2010).
  • The bigger risk is harm: potassium salt substitutes, unregulated herbs, high-dose vitamin C and NSAID painkillers can injure damaged kidneys (Te Dorsthorst 2019; Claure-Del Granado 2021; Lin 2019; Baker 2020).

Diabetic kidney disease (diabetic nephropathy) is kidney damage caused by diabetes. Doctors track it with urine albumin (the albumin-to-creatinine ratio, UACR) and eGFR (estimated glomerular filtration rate), a filtering measure calculated from blood creatinine and cystatin C (de Boer 2019). Most supplement trials measured only urine albumin: a lab marker, not proof that fewer people need dialysis.

What protects diabetic kidneys, if not supplements?

The KDIGO 2022 guideline on diabetes and chronic kidney disease (CKD) builds care on healthy habits, self-management and drugs: SGLT2 inhibitors first, then GLP-1 receptor agonists and finerenone, with control of blood pressure, glucose and blood fats (KDIGO 2022; Navaneethan 2023). None of those steps is a supplement.

In the FIDELIO-DKD trial of 5,734 people with CKD and type 2 diabetes, kidney failure, a lasting eGFR fall of at least 40%, or death from kidney causes occurred in 17.8% on finerenone and 21.1% on placebo over a median of 2.6 years (Bakris 2020).

Talk to your nephrologist (kidney doctor) first. When kidneys filter less, drugs and supplements can build up, so your care team needs to know every herb, supplement and over-the-counter product you use (Hall 2024).

Does vitamin D protect the kidneys in diabetes?

Grade B, no clear difference for kidney function. The VITAL kidney study gave 1,312 adults with type 2 diabetes vitamin D3 (2,000 IU a day), omega-3 (1 g a day), both, or placebos for 5 years. eGFR fell by 12.3 points with vitamin D3 and by 13.1 with placebo, a difference that was not statistically significant (de Boer 2019).

Grade C for urine albumin. A 2026 review of 11 systematic reviews found low-certainty evidence that vitamin D lowers urine albumin in diabetic kidney disease, with no consistent benefit for eGFR, dialysis or transplant, death or heart events (Vera-Ponce 2026). The authors see no kidney role for vitamin D beyond a deficiency or the bone and mineral problems of kidney disease, so take it only if a blood test shows you are low.

Does omega-3 (fish oil) help diabetic kidneys?

Grade B, no clear difference for kidney function. In the same trial, 1 g a day of omega-3 (EPA and DHA) gave an eGFR fall of 12.2 points against 13.1 with placebo, again not a significant difference (de Boer 2019). A 2026 meta-analysis of 12 randomized trials in 474 people with diabetic kidney disease found lower triglycerides and systolic blood pressure, but no significant change in UACR or eGFR (Zhang 2026).

Our diabetic nephropathy protocol lists omega-3 as a core supplement. On these trials we wouldn't take it, or fish oil, for the kidneys.

Does ginkgo lower protein in the urine?

Grade C. A 2024 meta-analysis pooled 41 randomized trials with 3,269 people with diabetic kidney disease. Ginkgo leaf extract taken with an ACE inhibitor or ARB lowered the urine albumin excretion rate, serum creatinine and 24-hour urine protein more than the drug alone, with no difference in side effects (Zhang 2024). Forty-one trials would normally earn a higher grade. We give C because every result was a lab marker (no trial counted kidney failure or heart events) and the authors ask for long-term studies.

Does alpha-lipoic acid help diabetic nephropathy?

Grade C. A 2021 meta-analysis of 11 randomized trials (1,294 people with diabetic nephropathy) found that alpha-lipoic acid (ALA) plus valsartan, an ARB, cut urine albumin more than either one alone (Sun 2021). As with ginkgo, that is a lab marker, measured alongside a prescribed drug.

Do turmeric and curcumin help?

Grade C, mixed results. Forty people with type 2 diabetic nephropathy took three 500 mg turmeric capsules a day or starch capsules for 2 months. Urine protein fell from its starting level on turmeric; the abstract gives no direct comparison with placebo (Khajehdehi 2011). Pooled, five trials of curcumin in 290 people with diabetic kidney disease found lower creatinine but no significant effect on urine protein (Jie 2021), and 12 trials in 1,303 people with diabetes found no significant change in creatinine (Bahari 2026).

Do benfotiamine or thiamine help?

Grade D, no clear difference for benfotiamine. Benfotiamine, a form of vitamin B1 (thiamine), was tested at 900 mg a day for 12 weeks in 82 people with type 2 diabetes and albumin in the urine despite an ACE inhibitor or ARB. Thiamine levels rose, but urine albumin did not fall (Alkhalaf 2010).

Grade D for plain thiamine. In a pilot trial of 21 men and 19 women with type 2 diabetes and slightly raised urine albumin, 100 mg of thiamine three times a day for 3 months left urine albumin lower than placebo: 30.1 against 35.5 mg per 24 hours (Rabbani 2009). Our protocol page's "dramatically" overstates one small pilot.

Do probiotics help diabetic kidney disease?

Grade C, mixed results. A 2026 meta-analysis of 11 randomized trials (726 people) found lower creatinine and higher eGFR with probiotics, but no significant change in UACR, 24-hour urine protein or cystatin C (Huang 2026). In a crossover trial of 41 adults with type 1 diabetes and albuminuria, 12 weeks of a probiotic and fiber mix had no effect on UACR or other measures (Stougaard 2024).

What about resveratrol, silymarin, green tea and saffron?

Each has one small trial in diabetic kidney disease, so each claim below is Grade D.

  • Resveratrol: 500 mg a day for 90 days, added to losartan in 60 people, lowered UACR by 46.4 mg/g while it rose 29.9 mg/g on placebo (Sattarinezhad 2019).
  • Silymarin (milk thistle extract): three 140 mg tablets a day for 3 months lowered UACR more than placebo in 60 people (Fallahzadeh 2012).
  • Green tea polyphenols: 800 mg of EGCG a day for 12 weeks cut UACR by 41% in 42 people, against a 2% rise on placebo (Borges 2016). That is more than twice the 338 mg a day a safety review set for EGCG in capsules or tablets (Hu 2018).
  • Saffron: 100 mg daily for 12 weeks in 80 adults with type 2 diabetes lowered systolic blood pressure; creatinine, urea and 24-hour urine albumin matched placebo (Ebrahimi 2019).

Should you take sodium bicarbonate for kidney disease?

Grade C, no clear benefit. Sodium bicarbonate is prescribed for metabolic acidosis (too much acid in the blood), which is common in older people with CKD. Don't start it on your own. In the BiCARB trial, 300 adults aged 60 or older with an eGFR below 30 took up to 3 g a day or a placebo for up to 2 years. Neither physical nor kidney function improved, and adverse events were more frequent: 457 against 400 (BiCARB 2020).

What we'd skip

  • Coenzyme Q10 for the kidneys: a 2019 meta-analysis found only 4 randomized trials, with no improvement in urea (Zhang 2019), and one CoQ10 trial in diabetic nephropathy was retracted (Gholnari 2018). Grade D.
  • "Kidney cleanse" blends and imported herbal remedies: no published trials, and a contamination risk (below).

Safety and interactions: what to avoid

Talk to your nephrologist (kidney doctor) first, and bring every bottle you take.

Potassium pills and potassium salt substitutes

Salt substitutes can hold about 440 mg to 2,800 mg of potassium per teaspoon. ACE inhibitors and ARBs reduce how much potassium the kidneys clear, and NIH advises people with kidney disease or on such drugs to ask a clinician first (NIH ODS potassium fact sheet).

Finerenone raises potassium too: 2.3% of people on it stopped because of high potassium, against 0.9% on placebo (Bakris 2020). High blood potassium (hyperkalemia) can cause dangerous heart rhythms. In 35 case reports (44 episodes) of hyperkalemia from food or supplements, salt substitutes caused 12 episodes; three people died, all with normal kidney function (Te Dorsthorst 2019).

High-dose vitamin C

High vitamin C intakes can raise urine oxalate, especially in people with kidney disorders (NIH ODS vitamin C fact sheet). Oxalate can form crystals that damage the kidney (Lamarche 2011). A case report describes acute kidney injury in a patient taking 2 g of vitamin C a day who had had bowel surgery (Lin 2019).

Herbal products and contamination

An herb can injure the kidneys through its own chemistry, or because the product was adulterated, contaminated, swapped for another plant or mislabeled (Claure-Del Granado 2021). Aristolochic acid, found in some traditional herbal remedies, causes fast-progressing kidney scarring that no treatment is known to slow or reverse (Zhou 2023).

NSAID painkillers

Ibuprofen, naproxen and other NSAIDs (non-steroidal anti-inflammatory drugs) aren't supplements, but in CKD they are linked to acute kidney injury, faster eGFR loss, blood-salt imbalances and fluid build-up (Baker 2020). Ask a pharmacist which pain reliever suits your kidneys.

Magnesium and phosphorus

Magnesium toxicity becomes more likely as kidney function falls (NIH ODS magnesium fact sheet). Among 320 hospital patients prescribed magnesium oxide, 23% developed high blood magnesium, and an eGFR of 55.4 or lower meant about three times the odds (Wakai 2019).

Phosphate added to processed foods is absorbed more fully than phosphorus in plant foods, and in CKD extra phosphorus is linked to faster kidney decline and heart damage (Cupisti 2025).

Licorice

Large amounts of real licorice make the body act as if it has too much aldosterone, a hormone that holds on to salt. In 104 case reports, high blood pressure and low potassium were the usual signs (Ceccuzzi 2023).

Creatine and kidney blood tests

Creatine raises serum creatinine, the value eGFR is calculated from (de Boer 2019). Across 19 randomized trials it raised creatinine by 0.13 mg/dL on average, with no difference in eGFR (Tsiaras 2026); a second review put the rise down to creatine turnover, not kidney harm (Naeini 2025). Tell whoever orders your kidney tests if you take it.

Other interactions

  • Ginkgo: 15 case reports linked it to bleeding, though most of those people had other bleeding risks (Bent 2005). Ask first if you take a blood thinner.
  • Alpha-lipoic acid can trigger insulin autoimmune syndrome, in which antibodies to insulin cause repeated low blood sugar (Vallianou 2026).
  • Omega-3 and vitamin D3: in the 5-year trial there were 28 gut bleeds on omega-3 against 17 on placebo, and 32 kidney stones on vitamin D3 against 26 (de Boer 2019).
  • Curcumin, probiotics, resveratrol and silymarin: no interaction studies with kidney or diabetes medicines were found.

Upper limits and doses

Adult upper limits, set for healthy people, are 4,000 IU a day for vitamin D, 2,000 mg for vitamin C and 350 mg for magnesium from supplements (NIH ODS vitamin D; vitamin C; magnesium). With reduced kidney function, let your nephrologist set your amount.

Kidney disease also changes the right dose of many prescribed drugs (Hall 2024); your prescriber adjusts diabetes medicines. Don't stop a prescribed medicine on your own; ask the prescriber or pharmacist.

When to see a doctor

Talk to your nephrologist (kidney doctor) or diabetes team before you start any supplement, salt substitute or over-the-counter painkiller. Get care promptly for:

  • muscle weakness, vomiting, shortness of breath or an irregular heartbeat after starting a salt substitute, potassium pill or new blood-pressure drug: possible high potassium (Te Dorsthorst 2019);
  • swollen ankles, legs or eyelids, or much less urine than usual;
  • repeated low blood sugar after starting alpha-lipoic acid (Vallianou 2026);
  • unusual bleeding or bruising while taking ginkgo or fish oil with a blood thinner;
  • a sudden creatinine rise or eGFR fall on a routine test.

Ask how often your urine albumin and eGFR should be checked. If you're pregnant, breastfeeding or under 18, ask a clinician before trying any supplement.

FAQ

What supplements are good for kidney health in diabetes? None has been shown to lower the risk of kidney failure. Ginkgo and alpha-lipoic acid reduced urine albumin alongside a blood-pressure drug (grade C).

Does vitamin D or fish oil slow diabetic kidney disease? No. Over 5 years in 1,312 adults with type 2 diabetes, vitamin D3 and omega-3 made no clear difference to eGFR (grade B).

Are salt substitutes safe with kidney disease? Many contain potassium chloride, which can push blood potassium too high with weak kidneys or with an ACE inhibitor, ARB or finerenone. Ask your nephrologist first.

Can a supplement change my kidney test results? Yes. Creatine raises blood creatinine, which is used to calculate eGFR, so tell your doctor if you take it.

Sources

  1. de Boer IH, et al. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2019. PubMed 31703120 · doi:10.1001/jama.2019.17380
  2. Zhang Z, et al. The efficacy and safety of Ginkgo biloba L. leaves extract combined with ACEI/ARB on diabetic kidney disease: a systematic review and meta-analysis of 41 randomized controlled trials. Front Pharmacol. 2024. PubMed 39830333 · doi:10.3389/fphar.2024.1408546
  3. Sun F, et al. Effects of valsartan combined with α-lipoic acid on renal function in patients with diabetic nephropathy: a systematic review and meta-analysis. BMC Endocr Disord. 2021. PubMed 34465338 · doi:10.1186/s12902-021-00844-0
  4. Bahari H, et al. Effects of Curcumin/Turmeric Supplementation on Kidney Function in Individuals With Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2026. PubMed 41761990 · doi:10.1002/edm2.70189
  5. Huang ZQ, et al. Effects of probiotic supplementation on diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Front Microbiol. 2026. PubMed 42245504 · doi:10.3389/fmicb.2026.1760954
  6. Alkhalaf A, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care. 2010. PubMed 20413516 · doi:10.2337/dc09-2241
  7. Te Dorsthorst RPM, et al. Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients. Eur J Clin Nutr. 2019. PubMed 29588531 · doi:10.1038/s41430-018-0154-6
  8. Claure-Del Granado R, et al. Herbal Nephropathy. Contrib Nephrol. 2021. PubMed 34343992 · doi:10.1159/000517693
  9. Baker M, et al. NSAIDs in CKD: Are They Safe? Am J Kidney Dis. 2020. PubMed 32479922 · doi:10.1053/j.ajkd.2020.03.023
  10. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022. PubMed 36272764 · doi:10.1016/j.kint.2022.06.008
  11. Navaneethan SD, et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Ann Intern Med. 2023. PubMed 36623286 · doi:10.7326/M22-2904
  12. Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020. PubMed 33264825 · doi:10.1056/NEJMoa2025845
  13. Hall RK, et al. Drug stewardship in chronic kidney disease to achieve effective and safe medication use. Nat Rev Nephrol. 2024. PubMed 38491222 · doi:10.1038/s41581-024-00823-3
  14. Vera-Ponce VJ, et al. Efficacy and safety of vitamin D supplementation in diabetic kidney disease: an umbrella review of systematic reviews and meta-analyses. Front Nephrol. 2026. PubMed 42528624 · doi:10.3389/fneph.2026.1883351
  15. Zhang L, et al. The Impact of Omega Fatty Acids on DKD: A Multimodal Study Integrating Mendelian Randomization, Proteomic Mediation Analysis, and Meta-Analysis. FASEB J. 2026. PubMed 42517346 · doi:10.1096/fj.202601523R
  16. Khajehdehi P, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol. 2011. PubMed 21627399 · doi:10.3109/00365599.2011.585622
  17. Jie Z, et al. Effect of Curcumin on Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Evid Based Complement Alternat Med. 2021. PubMed 34899954 · doi:10.1155/2021/6109406
  18. Rabbani N, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. Diabetologia. 2009. PubMed 19057893 · doi:10.1007/s00125-008-1224-4
  19. Stougaard EB, et al. Effects of probiotics and fibers on markers of nephropathy, inflammation, intestinal barrier dysfunction and endothelial dysfunction in individuals with type 1 diabetes and albuminuria. The ProFOS Study. J Diabetes Complications. 2024. PubMed 39471704 · doi:10.1016/j.jdiacomp.2024.108892
  20. Sattarinezhad A, et al. Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial. Diabetes Metab. 2019. PubMed 29983230 · doi:10.1016/j.diabet.2018.05.010
  21. Fallahzadeh MK, et al. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis. 2012. PubMed 22770926 · doi:10.1053/j.ajkd.2012.06.005
  22. Borges CM, et al. The use of green tea polyphenols for treating residual albuminuria in diabetic nephropathy: A double-blind randomised clinical trial. Sci Rep. 2016. PubMed 27320846 · doi:10.1038/srep28282
  23. Hu J, et al. The safety of green tea and green tea extract consumption in adults - Results of a systematic review. Regul Toxicol Pharmacol. 2018. PubMed 29580974 · doi:10.1016/j.yrtph.2018.03.019
  24. Ebrahimi F, et al. The effect of saffron (Crocus sativus L.) supplementation on blood pressure, and renal and liver function in patients with type 2 diabetes mellitus: A double-blinded, randomized clinical trial. Avicenna J Phytomed. 2019. PubMed 31309071
  25. BiCARB study group. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial. BMC Med. 2020. PubMed 32268897 · doi:10.1186/s12916-020-01542-9
  26. Zhang X, et al. Effects of coenzyme Q10 intervention on diabetic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019. PubMed 31192915 · doi:10.1097/MD.0000000000015850
  27. Gholnari T, et al. The Effects of Coenzyme Q10 Supplementation on Glucose Metabolism, Lipid Profiles, Inflammation, and Oxidative Stress in Patients With Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Coll Nutr. 2018. Retracted in 2024. PubMed 29111905 · doi:10.1080/07315724.2017.1386140
  28. Lamarche J, et al. Vitamin C-induced oxalate nephropathy. Int J Nephrol. 2011. PubMed 21603151 · doi:10.4061/2011/146927
  29. Lin WV, et al. Ascorbic acid-induced oxalate nephropathy: a case report and discussion of pathologic mechanisms. CEN Case Rep. 2019. PubMed 30276648 · doi:10.1007/s13730-018-0366-6
  30. Zhou Q, et al. Overview of aristolochic acid nephropathy: an update. Kidney Res Clin Pract. 2023. PubMed 37448287 · doi:10.23876/j.krcp.22.211
  31. Wakai E, et al. Risk factors for the development of hypermagnesemia in patients prescribed magnesium oxide: a retrospective cohort study. J Pharm Health Care Sci. 2019. PubMed 30805197 · doi:10.1186/s40780-019-0133-7
  32. Cupisti A, et al. Dietary Phosphorus and Metabolic Health in CKD and ESKD. Clin J Am Soc Nephrol. 2025. PubMed 40111420 · doi:10.2215/CJN.0000000715
  33. Ceccuzzi G, et al. Liquorice Toxicity: A Comprehensive Narrative Review. Nutrients. 2023. PubMed 37764649 · doi:10.3390/nu15183866
  34. Tsiaras A, et al. The Effect of Creatine Supplementation on Kidney Function: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Ren Nutr. 2026. PubMed 42035842 · doi:10.1053/j.jrn.2026.04.010
  35. Naeini EK, et al. Effect of creatine supplementation on kidney function: a systematic review and meta-analysis. BMC Nephrol. 2025. PubMed 41199218 · doi:10.1186/s12882-025-04558-6
  36. Bent S, et al. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med. 2005. PubMed 16050865 · doi:10.1111/j.1525-1497.2005.0121.x
  37. Vallianou NG, et al. Alpha-lipoic acid as a trigger of insulin autoimmune syndrome: Current evidence, a case-based approach, diagnostic pitfalls, and practical management. Metabol Open. 2026. PubMed 42662728 · doi:10.1016/j.metop.2026.100491